MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
TransMedics Group Cost of Revenue 2011-2026 | TMDX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue TransMedics Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 243 M | 179 M | 87.5 M | 28.2 M | 9.1 M | 9 M | 9.74 M | 7.28 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 243 M | 7.28 M | 71.6 M |
Quarterly Cost of Revenue TransMedics Group
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60.8 M | 55.3 M | - | 47.9 M | 45 M | 36.9 M | - | 25.8 M | 15.7 M | 12.8 M | - | 7.57 M | 6.17 M | 3.78 M | - | 1.6 M | 2.58 M | 2.24 M | - | 2.05 M | 1.48 M | 2.67 M | - | 2.99 M | 2.33 M | 2.1 M | - | 1.91 M | 1.74 M | 1.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 60.8 M | 1.48 M | 14.9 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M |  USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 166.38 | -6.17 % | $ 12.5 B | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 33.72 | -4.58 % | $ 5.02 K | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 10.93 | -5.12 % | $ 1.64 B | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 9.07 | -3.41 % | $ 257 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 0.4 | 4.21 % | $ 41.1 M | USA |
 |
Abbott Laboratories
ABT
|
19.3 B | $ 103.99 | -0.55 % | $ 181 B | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Electromed
ELMD
|
14 M | $ 24.55 | 0.16 % | $ 208 M | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 69.17 | -1.43 % | $ 102 B | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Establishment Labs Holdings
ESTA
|
64.8 M | $ 55.31 | -7.68 % | $ 1.64 B |  Costa-rica |
 |
CONMED Corporation
CNMD
|
624 M | $ 34.58 | -5.7 % | $ 1.07 B | USA |
 |
NanoVibronix
NAOV
|
1.05 M | - | - | $ 1.08 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.59 | -1.18 % | $ 32.1 M | USA |
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.15 | -5.29 % | $ 3.36 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 79.34 | -3.36 % | $ 46.4 B | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 1.92 | -4.48 % | $ 1.17 M | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 0.99 | -26.67 % | $ 16 M | USA |
 |
IRadimed Corporation
IRMD
|
19.5 M | $ 97.36 | -1.4 % | $ 1.24 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 85.33 | -1.73 % | $ 2.96 B | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 11.2 | -1.84 % | $ 1.51 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 15.52 | -5.08 % | $ 364 M | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
161 K | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
14 M | $ 0.7 | 2.32 % | $ 29.3 M | USA |
 |
Penumbra
PEN
|
461 M | $ 335.1 | -0.39 % | $ 13 B | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 50.13 | -0.54 % | $ 1.47 B | USA |
 |
Pulmonx Corporation
LUNG
|
23.4 M | $ 1.17 | -5.65 % | $ 47.6 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |